Novartis plans to shut down Sandoz North Carolina plant by 2023 end
Zurich: Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.Read also: Novartis Sandoz...
Zurich: Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.
The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.
Read also: Novartis Sandoz division to go independent
It said the decision to close the site had come before it announced a strategic review of Sandoz, which it plans to spin off to sharpen the group's focus on patented prescription medicines.
